Biometry

Founded with a mission to revolutionize chronic disease management, myBiometry focuses on leveraging biomarker data and machine learning to monitor and manage patients' health. The company's core vision is to empower patients with actionable biological data to predict and prevent health crises. Initially targeting asthma, myBiometry has developed a single-use, disposable sensor that measures airway inflammation through fractional exhaled nitric oxide (FeNO). This data helps in identifying changes in medication adherence, treatment response, and risk of asthma attacks, aiming to reduce the high rate of treatment failures.

Notable figures associated with myBiometry include experts in biomedical engineering and healthcare technology. The company has attracted significant interest from investors focused on health tech innovations. Key achievements include the development and patenting of their proprietary sensor technology and successful pilot studies demonstrating its efficacy. Overall, myBiometry's impact lies in its potential to transform chronic disease management by providing real-time, actionable insights, thereby improving patient outcomes and reducing healthcare costs.